Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2015

01-07-2015 | Adis Drug Evaluation

Aflibercept: A Review of Its Use in Diabetic Macular Oedema

Author: Gillian M. Keating

Published in: Drugs | Issue 10/2015

Login to get access

Abstract

Aflibercept (Eylea®) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus macular laser photocoagulation in the phase III VISTA-DME and VIVID-DME trials, and versus intravitreal bevacizumab or ranibizumab in those with worse visual acuity at baseline (i.e. Early Treatment Diabetic Retinopathy Study letter score of <69) in the phase III PROTOCOL-T trial. Intravitreal aflibercept was generally well tolerated in patients with diabetic macular oedema. In conclusion, intravitreal aflibercept is an important new treatment for diabetic macular oedema.
Literature
1.
2.
Klein BEK. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–83.PubMedCrossRef
3.
Singh A, Stewart JM. Pathophysiology of diabetic macular edema. Int Ophthalmol Clin. 2009;49(2):1–11.PubMedCrossRef
4.
Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;10:CD007419.PubMed
5.
6.
Simó R, Sundstrom JM, Antonetti DA. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 2014;37(4):893–9.PubMedCrossRef
7.
Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575–83.PubMedCrossRef
8.
9.
10.
Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012;29(10):839–46.PubMedCrossRef
11.
Yang LPH, McKeage K. Intravitreal aflibercept (Eylea®): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging. 2014;31(5):395–404.PubMedCrossRef
12.
13.
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85.PubMedCentralPubMedCrossRef
14.
Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667–8.PubMedCrossRef
15.
Deissler HL, Lang GK, Lang GE. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Exp Eye Res. 2014;122(Suppl C):20–31.PubMedCrossRef
16.
Ammar DA, Mandava N, Kahook MY. The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina. 2013;33(5):1056–61.PubMedCrossRef
17.
Schnichels S, Hagemann U, Januschowski K, et al. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol. 2013;97(7):917–23.PubMedCrossRef
18.
Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014;98(Suppl 1):i11–6.PubMedCentralPubMedCrossRef
19.
Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195(2):241–8.PubMedCrossRef
20.
Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;93(2):144–9.PubMedCrossRef
21.
Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819–26.PubMedCrossRef
22.
Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–65.PubMedCrossRef
23.
Korobelnik J-F, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54.PubMedCrossRef
24.
The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1260–1.CrossRef
25.
Gonzalez VH, Boyer DS, Schmidt-Erfurth U, et al. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Retina. 2015;35(4):687–94.PubMedCrossRef
26.
Stewart MW. Aflibercept ophthalmic solution: drug development and clinical uses. Clin Investig. 2013;3(11):1045–56.CrossRef
27.
Christoforidis JB, Williams MM, Kothandaraman S, et al. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37(12):1171–4.PubMedCrossRef
28.
Stewart MW. What are the half-lives of ranbizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep. 2011;1(1):e5.CrossRef
29.
Varano M, for the VIVID-DME/VISTA-DME Study Investigators. Evaluation of the efficacy and safety of intravitreal aflibercept in patients with diabetic macular edema: 100-week results from the VIVID-DME and VISTA-DME studies [poster]. In: 6th World Congress on Controversies in Ophthamology. 2015.
30.
McAllister I, Holz F, Metzig C. Time course of visual acuity changes with intravitreal aflibercept (IVT-AFL) or macular laser photocoagulation in patients with diabetic macular edema (DME): outcomes from the VIVID-DME and VISTA-DME clinical trials [abstract no. 0504]. Clin Exp Ophthalmol. 2014;42(Suppl 1):13.
31.
Metzig C. Diabetic macular oedema and diabetic retinopathy: treatment outcomes with aflibercept do not depend on systemic diabetes control [abstract no. 54]. Diabetologia. 2014;57(Suppl 1):S29.
32.
Lorenz K. Evaluation of intravitreal aflibercept for treatment of diabetic macular edema: visual acuity subgroups in VIVID-DME and VISTA-DME [abstract no. 5054]. In: AVRO 2014 Annual Meeting. 2014.
33.
Hahn P, Chung MM, Flynn HW Jr, et al. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmol. 2015;133(4):421–6.PubMedCrossRef
34.
Fine HF, Roth DB, Shah SP, et al. Frequency and characteristics of intraocular inflammation after aflibercept injection. Retina. 2015;35(4):681–6.PubMedCrossRef
35.
Rodriguez M, Storey P, Do DV. Anti-VEGF therapy for the management of diabetic macular edema. Curr Ophthalmol Rep. 2013;1(3):122–7.CrossRef
36.
American Diabetes Association. Standards of medical care in diabetes: 2015. Diabetes Care. 2015;38(Suppl 1):S1–93.
37.
38.
39.
Wykoff CC, Hariprasad SM. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015;46(3):302–5.PubMedCrossRef
40.
Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.PubMedCrossRef
41.
Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–86.e2.PubMedCrossRef
42.
Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Basingstoke). 2013;27(7):787–94.
43.
Schwartz SG, Flynn HW, Scott IU. Emerging drugs for diabetic macular edema. Expert Opin Emerg Drugs. 2014;19(3):397–405.PubMedCrossRef
44.
O’Malley PG. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions. Arch Intern Med. 2012;172(13):1014–5.PubMed
45.
Martin DF, Maguire MG. Treatment choice for diabetic macular edema. N Engl J Med. 2015;372(13):1260–1.PubMedCrossRef
46.
Terasaki H. Efficacy and safety of intravitreal aflibercept injection for diabetic macular edema in Japanese patients: analysis of the VIVID-DME, VISTA-DME, and VIVID-Japan studies [abstract no. FP-FR-20]. In: World Ophthalmology Congress 2014. 2014.
Metadata
Title
Aflibercept: A Review of Its Use in Diabetic Macular Oedema
Author
Gillian M. Keating
Publication date
01-07-2015
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0421-y

Other articles of this Issue 10/2015

Drugs 10/2015 Go to the issue

Adis Drug Evaluation

Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting

Review Article

Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection

Leading Article

Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis

Review Article

Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention

Adis Drug Evaluation

Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis

Leading Article

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions